WASHINGTON (MarketWatch) — More than four in 10 institutional investors say their “say on pay” vote doesn’t end up influencing how company executives are paid, according to a new study from Stanford Graduate School of Business.
Perhaps equally worrisome for small investors, who rely on money managers to represent their interests, just one in four of those professionals said they understand the way executives will receive payouts under long-term performance plans.
The findings come after the Securities and Exchange Commission in 2011 began requiring nonbinding shareholders vote on executive compensation at least once every three years, under the Dodd-Frank financial reform law.
Feb 17, 2015, Eric Garcia, Reporter
Read the rest here.
Tuesday, March 3, 2015
Blue Cross top executive gets big raise, lower overall compensation
The release Friday of Blue Cross and Blue Shield of N.C.’s executive compensation for 2014 reopens the debate about what is fair and competitive for a not-for-profit health system to offer.
Brad Wilson, its chief executive and president, received a 5.6 percent raise in salary to $947,862. His bonus decreased 13 percent to $1.8 million. Total compensation was $2.83 million, down 4.7 percent from 2013, but up 13.9 percent from 2012.
Friday, February 27, 2015,
Read more here.
Brad Wilson, its chief executive and president, received a 5.6 percent raise in salary to $947,862. His bonus decreased 13 percent to $1.8 million. Total compensation was $2.83 million, down 4.7 percent from 2013, but up 13.9 percent from 2012.
Friday, February 27, 2015,
Read more here.
Thursday, January 8, 2015
Step aside Wall Street, small pharma CEO pay reaches for the sky
An examination of biopharma company CEO salaries shows that many are paid like a hybrid of entrepreneurs and blue chip company CEOs, giving these executives the best of both worlds.
They may not be running too big to fail firms, but the CEOs of many small biopharmaceutical companies are being paid like they are unquestionably indispensable, In fact, many are making more than Wall Street’s chief executives and the CEOs of their much larger pharmaceutical peers.
Read the rest here.
Target Chief's $47 Million Retirement and America's 401(k) Gap
The gap in the U.S. workplace between the highest and lowest paid has been growing for years. Far less noticed has been the growing gulf in retirement pay.
While the very top often continue to receive executive pensions as well as other benefits, most workers are left only with their 401(k) plans.
Pay package swells for Jabil CEO Mark Mondello
Jabil Circuit Inc.'s board of directors boosted compensation for CEO Mark Mondello in an effort similar to keeping up with the Jones'.
Mondello got a 40 percent boost in pay in fiscal 2014, ended Aug. 31, and received total compensation of $6.5 million for the year, according to a proxy filed with theU.S. Securities and Exchange Commission. He received $4.7 million in total compensation in the previous year.
Tuesday, December 9, 2014
Tuesday, November 25, 2014
Advanced Micro Shareholder Sues Over New CEO’s Stock Grant
An Advanced Micro Devices Inc. (AMD) investor accused company directors of violating an executive-compensation plan by giving new Chief Executive Officer Lisa Su more than 6 million shares as part of her pay package.
Su, tapped to run the troubled computer chipmaker last month, was awarded more than 6.4 million AMD shares in violation of the company’s pay plan, which limits such awards to 3 million shares per year, shareholder Thuan Hong said today in a Delaware Chancery Court lawsuit.
Nov 24, 2014 9:07 PM, BloombergRead more here.
Subscribe to:
Posts (Atom)